[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:chronic-myelomonocytic-leukemia:hla-class-i-histocompatibility-antigen-a-0201-alpha-chain":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Chronic Myelomonocytic Leukemia","HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06383572","Phase I\u002FII Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Myeloid Malignancies",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:50.539717Z","2026-05-05T02:43:29.502354Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06994676","A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias",[20],"Phase 1","2026-08-26T02:18:41.390601Z","2026-05-05T02:43:27.517921Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT03326921","HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant",[20],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.769481Z"]